Stocks and Investing Stocks and Investing
Mon, August 6, 2018
Fri, August 3, 2018

Matthew Harrison Maintained (BMRN) at Buy with Increased Target to $115 on, Aug 3rd, 2018


Published on 2024-10-26 07:39:39 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $113 to $115 on, Aug 3rd, 2018.

Matthew has made no other calls on BMRN in the last 4 months.



There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Matthew


  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $113 on, Tuesday, July 31st, 2018
  • M. Auster of "Credit Suisse" Maintained at Buy with Increased Target to $122 on, Monday, July 9th, 2018
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Increased Target to $133 on, Thursday, May 31st, 2018
  • Liana Moussatos of "Wedbush" Maintained at Buy with Increased Target to $115 on, Tuesday, May 29th, 2018
Contributing Sources